Previous 10 | Next 10 |
Seneca Biopharma (SNCA) received a notification letter from Nasdaq granting 180-day extension to regain compliance with Nasdaq's minimum bid price requirement. The company now has until June 9, 2021 to meet the bid price requirement.Shares are up 3...
Seneca Biopharma Granted 180-Day Extension by NASDAQ to Regain Compliance with Bid Price Rule GERMANTOWN, Md. , Dec. 15, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high un...
Seneca Biopharma (NASDAQ: SNCA ) perks 8% premarket on the heels of announcement that the last subject completed their final follow-up assessment in Company's non-GCP Phase II study in China evaluating NSI-566 for the treatment of chronic ischemic stroke. More news on:...
GERMANTOWN, Maryland , Sept. 10, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today announced that the last subject completed their final follow-up assessment in...
GERMANTOWN, Md. , Sept. 2, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today provided the following letter from Dr. Ken Carter , the Company's Executive Chairm...
Seneca Biopharma (NASDAQ: SNCA ) : Q2 GAAP EPS of -$0.15. At June 30, cash was ~$15.8M as compared to ~$10M at March 31, 2020. Press Release More news on: Seneca Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, ,
GERMANTOWN, Md. , Aug. 13, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today reported its financial results for the quarter ended June 30, 2020 . Business Highli...
GERMANTOWN, Md. , Aug. 10, 2020 /PRNewswire/ -- Limited to the following proposals: Proposal 3 – To ratify the filing and effectiveness of the amendment to the Company's amended and restated certificate of incorporation that was filed with the Secretary of Stat...
GERMANTOWN, Md. , May 27, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq:SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet medical need, today announced the closing of its previously announced $5 million registered...
Gainers: Navidea Biopharmaceuticals (NYSEMKT: NAVB ) +92% . More news on: Navidea Biopharmaceuticals, Inc., XpresSpa Group, Inc., Celsion Corporation, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Neuralstem Inc. Company Name:
SNCA Stock Symbol:
NYSE Market:
Alzheimer’s disease (AD) is the most common cause of dementia, a progressively debilitating neurodegenerative disease that results in declining cognitive functions, inability to form new memories, behavioral disorders, and gradual loss of bodily functions. While older age does not cause...
In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...
Seneca Biopharma Announces Successful Approval of Merger with Leading Biosciences, Inc. - Proposed merger with Leading Biosciences, Inc. expected to close on or about Tuesday, April 27th, 2021 - New combined company, Palisades Bio, expected to begin trading on Nasdaq Capital...